文献速递肿瘤 PET/CT核素与放射性配体治疗

双示踪剂PET/CT靶向、mpMRI靶向、系统穿刺与联合穿刺诊断前列腺癌:一项先导研究

Dual-tracer PET/CT-targeted, mpMRI-targeted, systematic biopsy, and combined biopsy for the diagnosis of prostate cancer: a pilot study.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2021-12-03

该先导研究纳入112例疑似前列腺癌患者,比较mpMRI靶向穿刺、双示踪剂(GRPR和PSMA)PET/CT靶向穿刺、系统穿刺及联合穿刺的诊断效能。68Ga-PSMA PET/CT靶向穿刺的前列腺癌检出率(69.77%)和穿刺针阳性率(0.44)分别高于系统穿刺(39.29%和0.12)及mpMRI靶向穿刺(36.14%和0.23)(P < 0.005)。双示踪剂PET/CT筛选可使52.67%(59/112)患者避免不必要的穿刺,双示踪剂PET/CT靶向穿刺联合系统穿刺检出率达77.36%且未漏诊临床显著前列腺癌。

要点

  • 68Ga-PSMA PET/CT靶向穿刺前列腺癌检出率69.77%,高于系统穿刺39.29%和mpMRI靶向穿刺36.14%(P < 0.005)。
  • 双示踪剂PET/CT筛选可使52.67%(59/112)患者避免不必要的穿刺。
  • 双示踪剂PET/CT靶向穿刺联合系统穿刺检出率77.36%,未漏诊临床显著前列腺癌。

核心结论

  • 双示踪剂PET/CT可能通过筛选患者避免不必要的穿刺。
  • 双示踪剂PET/CT靶向穿刺联合系统穿刺可能是比mpMRI靶向穿刺更有效且更有前景的临床显著前列腺癌确诊策略。

研究设计与样本

  • 先导研究,2020年9月至2021年6月纳入112例疑似前列腺癌患者。
  • 双示踪剂PET/CT或mpMRI任一阳性者接受靶向穿刺,所有入组患者在靶向穿刺后接受系统穿刺。
  • 主要结局为不同穿刺策略的前列腺癌检出率;次要结局为三种影像方法的表现、漏诊率及不同穿刺策略活检样本相对于前列腺切除标本的升级和降级。
  • 采用McNemar检验和Bonferroni校正进行多重比较。

主要发现

  • 112例中,临床显著前列腺癌(GG ≥ 2)占34.82%(39/112),非临床显著前列腺癌(GG = 1)占4.46%(5/112)。
  • 68Ga-PSMA PET/CT靶向穿刺前列腺癌检出率为69.77%,穿刺针阳性率为0.44。
  • 系统穿刺前列腺癌检出率为39.29%,穿刺针阳性率为0.12;mpMRI靶向穿刺前列腺癌检出率为36.14%,穿刺针阳性率为0.23;68Ga-PSMA PET/CT靶向穿刺分别与两者比较,P < 0.005。
  • 双示踪剂PET/CT筛选使52.67%(59/112)患者避免不必要的穿刺。
  • 双示踪剂PET/CT靶向穿刺联合系统穿刺检出率达77.36%,且未漏诊临床显著前列腺癌。

关键数值与推荐

  • 临床显著前列腺癌定义为GG ≥ 2,占34.82%(39/112);非临床显著前列腺癌为GG = 1,占4.46%(5/112)。
  • 68Ga-PSMA PET/CT靶向穿刺检出率69.77%、穿刺针阳性率0.44;系统穿刺检出率39.29%、穿刺针阳性率0.12;mpMRI靶向穿刺检出率36.14%、穿刺针阳性率0.23;68Ga-PSMA PET/CT靶向穿刺与后两者比较P < 0.005。
  • 双示踪剂PET/CT筛选避免穿刺比例52.67%(59/112)。
  • 双示踪剂PET/CT靶向穿刺联合系统穿刺检出率77.36%,未漏诊临床显著前列腺癌。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Growing evidence proved the efficacy of multi-parametric MRI (mpMRI) and prostate-specific membrane antigen (PSMA) positron emission tomography/computed tomography (PET/CT)-guided targeted biopsy (TB) in prostate cancer (PCa) diagnosis, but there is no direct comparison between mpMRI-TB and PSMA PET/CT-TB. Gastrin-releasing peptide receptor (GRPR) is highly expressed in PCa, which can compensate for the unstable expression of PSMA in PCa. Therefore, we designed a study to compare the efficiency of mpMRI-TB, dual-tracer (GRPR and PSMA) PET/CT-TB, systematic biopsy, and combined biopsy for the diagnosis of prostate cancer. METHODS: One hundred twelve suspicious PCa patients were enrolled from September 2020 to June 2021. Patients with anyone of positive dual-tracer PET/CT or mpMRI underwent TB, and all enrolled patients underwent systematic biopsy (SB) after TB. The primary outcome was the detection rates of PCa in different biopsy strategies. Secondary outcomes were the performance of three imaging methods, omission diagnostic rates, and upgrading and downgrading of biopsy samples relative to those of prostatectomy specimens in different biopsy strategies. McNemar's tests and Bonferroni correction in multiple comparisons were used to compare the primary and secondary outcomes. RESULTS: In 112 men, clinically significant PCa (grade group[GG] ≥ 2) accounted for 34.82% (39/112), and nonclinically significant PCa (GG = 1) accounted for 4.46% (5/112). 68 Ga-PSMA PET/CT-TB achieved higher PCa detection rate (69.77%) and positive ratio of biopsy cores (0.44) compared with SB (39.29% and 0.12) and mpMRI-TB (36.14% and 0.23), respectively (P < 0.005). Dual-tracer PET/CT screen out patients for avoiding 52.67% (59/112) unnecessary biopsy, whereas dual-tracer PET/CT-TB plus SB achieved high detection rate (77.36%) without misdiagnosis of csPCa. CONCLUSION: Dual-tracer PET/CT might screen patients for avoiding unnecessary biopsy. Dual-tracer PET/CT-TB plus SB might be a more effective and promising strategy for the definite diagnosis of clinically significant PCa than mpMRI-TB.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Qiu DX, Li J, Zhang JW, et al. Dual-tracer PET/CT-targeted, mpMRI-targeted, systematic biopsy, and combined biopsy for the diagnosis of prostate cancer: a pilot study. Eur J Nucl Med Mol Imaging. 2021. PMID: 34860277. doi:10.1007/s00259-021-05636-1

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。